Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy

Cancer Research

Volumn 62, Issue 19, 2002, Pages 5476-5484

  Pietras, Kristian ^a   Rubin, Kristofer ^b   Sjöblom, Tobias ^a   Buchdunger, Elisabeth ^c   Sjöquist, Mats ^b   Heldin, Carl Henrik ^a   Östman, Arne ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; FLUOROURACIL; IMATINIB; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STROMA; TUMOR; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG SYNERGISM; FLUOROURACIL; MICE; MICE, SCID; PACLITAXEL; PIPERAZINES; PYRIMIDINES; RATS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION; STROMAL CELLS; SWINE; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036790060     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Gullino, P., Clark, S., and Grantham, F. The interstitial fluid of solid tumors. Cancer Res., 24: 780-797, 1964.
2. Jain, R. K. Transport of molecules in the tumor interstitium: a review. Cancer Res., 47: 3039-3051, 1987.
3. Curti, B. D. Physical barriers to drug delivery in tumors. In: B. A. Chabner and L. D. L. (eds.), Cancer Chemotherapy and Biotherapy, pp. 709-719. Philadelphia: Lippincott-Raven, 1996.
4. Jain, R. K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev., 26: 71-90, 1997.
5. Brekken, C., Hjelstuen, M. H., Bruland, O. S., and de Lange Davies, C. Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human osteosarcoma xenografts. Anticancer Res., 20: 3513-3519, 2000.
6. Netti, P. A., Hamberg, L. M., Babich, J. W., Kierstead, D., Graham, W., Hunter. G. J., Wolf, G. L., Fischman, A., Boucher, Y., and Jain, R. K. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl. Acad. Sci. USA, 96: 3137-3142, 1999.
7. Pietras, K., Ostman, A., Sjoquist, M., Buchdunger, E., Reed, R. K., Heldin, C-H., and Rubin, K. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res., 61: 2929-2934, 2001.
8. Rubin, K., Sjoquist, M., Gustafsson, A. M., Isaksson, B., Salvessen, G., and Reed, R. K. Lowering of tumoral interstitial fluid pressure by prostaglandin E(1) is paralleled by an increased uptake of (51)Cr-EDTA. Int. J. Cancer, 86: 636-643, 2000.
9. Boucher, Y., and Jain, R. K. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res., 52: 5110-5114, 1992.
10. Brekken, C., Bruland, O. S., and de Lange Davies, C. Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase. Anticancer Res., 20: 3503-3512, 2000.
11. Rodt, S. A., Ahlen, K., Berg, A., Rubin, K., and Reed, R. K. A novel physiological function for platelet-derived growth factor-BB in rat dermis. J. Physiol., 495: 193-200, 1996.
12. Jain, R. K. Microcirculation and transport phenomena in tumours. In: R. K. Reed and K. Rubin (eds.). Connective Tissue Biology. Integration and Reductionism. pp. 269-293. London: Portland Press, 1997.
13. Ostman, A., and Heldin, C. H. Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv. Cancer Res., 80: 1-38, 2001.
14. Green, L. S., Jellinek, D., Jenison, R., Ostman, A., Heldin, C. H., and Janjic, N. Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry, 35: 14413-24, 1996.
15. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B. J., and Lydon, N. B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 56: 100-104, 1996.
16. Capdeville, R., Buchdunger, E., Zimmerman, J., and Matter, A. Glivec (ST1571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1: 493-502, 2002.
17. United Kingdom Co-ordinating Committee on Cancer Res. (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br. J. Cancer, 77: 1-10, 1998.
18. Ain, K. B., Tofiq, S., and Taylor, K. D. Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J. Clin. Endocrinol. Metab., 81: 3650-3653, 1996.
19. Floege, J., Ostendorf, T., Janssen, U., Burg, M., Radeke, H. H., Vargeese, C., Gill, S. C., Green, L. S., and Janjic, N. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am. J. Pathol., 154: 169-179, 1999.
20. Claesson-Welsh, L., Eriksson, A., Moren, A., Severinsson, L., Ek, B., Ostman, A., Betsholtz, C., and Heldin, C. H. cDNA cloning and expression of a human platelet-derived growth factor (PDGF) receptor specific for B-chain-containing PDGF molecules. Mol. Cell. Biol., 8: 3476-3486, 1988.
21. Sjoblom, T., Shimizu, A., O'Brien, K. P., Pietras, K., Dal Cin, P., Buchdunger, E., Dumanski, J. P., Ostman, A., and Heldin, C-H. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res., 61: 5778-5783, 2001.
22. Wassberg, E., Hedborg, F., Skoldenberg, E., Stridsberg, M., and Christofferson, R. Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma. Am. J. Pathol., 154: 395-403, 1999.
23. Browder, T., Butterfield, C. E., Kraling, B. M., Shi, B., Marshall, B., O'Reilly, M. S., and Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60: 1878-1886, 2000.
24. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., and Kerbel, R. S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Investig., 105: R15-R24, 2000.
25. Larsson, H., Sjoblom, T., Dixelius, J., Ostman, A., Ylinenjarvi, K., Bjork, I., and Claesson-Welsh, L. Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. Cancer Res., 60: 6723-6729, 2000.
26. Griffon-Etienne, G., Boucher, Y., Brekken, C., Suit, H. D., and Jain, R. K. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res., 59: 3776-3782, 1999.
27. Less, J. R., Posner, M. C., Boucher, Y., Borochovitz, D., Wolmark, N., and Jain, R. K. Interstitial hypertension in human breast and colorectal tumors. Cancer Res., 52: 6371-6374, 1992.
28. Nathanson, S. D., and Nelson, L. Interstitial fluid pressure in breast cancer, benign breast conditions, and breast parenchyma. Ann. Surg. Oncol., 1: 333-338, 1994.
29. Boucher, Y., Kirkwood, J. M., Opacic, D., Desantis, M., and Jain, R. K. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res. 51: 6691-6694, 1991.
30. Curti, B. D., Urba, W. J., Alvord, W. G., Janik, J. E., Smith,. J. W., II, Madara, K., and Longo, D. L. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res., 53: 2204-2207, 1993.
31. Gutmann, R., Leunig, M., Feyh, J., Goetz, A. E., Messmer, K., Kastenbauer, E., and Jain, R. K. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res., 52: 1993-1995, 1992.
32. Lee, I., Boucher, Y., and Jain, R. K. Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res., 52: 3237-3240, 1992.
33. Kristjansen, P. E., Boucher, Y., and Jain, R. K. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res., 53: 4764-4766, 1993.
34. Kristensen, C. A., Nozue, M., Boucher, Y., and Jain, R. K. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br. J. Cancer. 74: 533-536, 1996.
35. Brekken, C., and de Lange Davies, C. Hyaluronidase reduces the interstitial fluid pressure in solid tumours in a non-linear concentration-dependent manner. Cancer Lett., 131: 65-70, 1998.
36. Emerich, D. F., Dean, R. L., Snodgrass, P., Lafreniere, D., Agostino, M., Wiens, T., Xiong, H., Hasler, B., Marsh, J., Pink, M., Kim, B. S., Perdomo, B., and Bartus, R. T. Bradykinin modulation of tumor vasculature: 11. activation of nitric oxide and phospholipase A2/prostaglandin signaling pathways synergistically modifies vascular physiology and morphology to enhance delivery of chemotherapeutic agents to tumors. J. Pharmacol. Exp. Ther., 296: 632-641, 2001.
37. Lee. C. G., Heijn, M., di Tomaso, E., Griffon-Etienne, G., Ancukiewicz, M., Koike, C., Park, K. R., Ferrara, N., Jain, R. K., Suit, H. D., and Boucher, Y. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res., 60: 5565-5570, 2000.
38. Milosevic, M., Fyles, A., Hedley, D., Pintilie, M., Levin, W., Manchul, L., and Hill, R. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res., 61: 6400-6405, 2001.
39. Reed, R. K., Berg, A., Gjerde, E. A., and Rubin, K. Control of interstitial fluid pressure: role of beta1-integrins. Semin. Nephrol., 21: 222-230, 2001.
40. Rubin. K., Gullberg, D., Tomasini-Johansson, B., Reed, R. K., Rydén, C., and Borg, T. K. Molecular recognition of the extracellular matrix by cell surface receptors. In: W. D. Comper (ed.) Structure and Function of the Extracellular Matrix of Connective Tissues, pp. 262-230. London: Portland Press, 1996.
41. Heuchel, R., Berg, A., Tallquist, M., Ahlen, K., Reed, R. K., Rubin, K., Claesson-Welsh, L., Heldin, C. H., and Soriano, P. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling. Proc. Natl. Acad. Sci. USA. 96: 11410-5, 1999.
42. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
43. van Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., Donato di Paola, E., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., Silberman, S., and Nielsen, O. S. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet, 358: 1421-1423, 2001.